Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 14/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.47 |
| ▸ | MIF | P14174 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16600991 | 0.86 | ALDH1A1 (0.46) | P4HTMKDM4EALDH1A1GRIN2BKEAP1 | |
| SCHEMBL25734158 | 0.83 | P4HTM (0.50) | P4HTMKDM4EMAPK1L3MBTL1ALDH1A1 | |
| SCHEMBL16600880 | 0.81 | GRIN2B (0.47) | P4HTMKDM4EALDH1A1GRIN2BKEAP1 | |
| SCHEMBL1201332 | 0.79 | IGFBP3 (0.47) | P4HTMMMP2ALDH1A1 | |
| SCHEMBL13548255 | 0.77 | HPGD (0.46) | KDM4EALDH1A1KEAP1 | |
| SCHEMBL8869353 | 0.76 | P4HTM (0.57) | P4HTMMAPK1ALDH1A1 | |
| SCHEMBL23384342 | 0.76 | GRIN2B (0.38) | P4HTMGRIN2BKEAP1 | |
| SCHEMBL3621496 | 0.76 | P4HTM (0.59) | P4HTMKDM4EMAPK1L3MBTL1P4HA1 | |
| SCHEMBL21485440 | 0.75 | GRIN2B (0.48) | P4HTMALDH1A1GRIN2B | |
| SCHEMBL3621493 | 0.75 | P4HTM (0.63) | P4HTMKDM4EMAPK1L3MBTL1P4HA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383824-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2013-02-26 | — | — | US | claimed |
| CN-102639504-A | Heterocyclic antiviral compounds | HOFFMANN LA ROCHE | 2012-08-15 | — | — | CN | claimed |
| CN-102099335-A | Heterocyclic antiviral compounds | HOFFMANN LA ROCHE | 2011-06-15 | — | — | CN | claimed |
| WO-2010010017-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-01-28 | — | — | WO | claimed |
| US-20100021423-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2010-01-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100021423-A1 | Heterocyclic antiviral compounds | POLR2A, RRM2B, RRP1B | P4HTM 1917/4885KDM4E 1962/4885MAPK1 3018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.